<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3764">
  <stage>Registered</stage>
  <submitdate>6/01/2013</submitdate>
  <approvaldate>6/01/2013</approvaldate>
  <nctid>NCT01763242</nctid>
  <trial_identification>
    <studytitle>Study of the Effect of Synchronised Anaemia Management in Chronic Kidney Disease</studytitle>
    <scientifictitle>EMAN-Anaemia: An Open Labelled Randomised Control Trial of the Synchronized Electronic MANagement of Anaemia in Chronic Kidney Disease (CKD) Compared to Usual Care Anaemia Management</scientifictitle>
    <utrn />
    <trialacronym>EMAN-Anaemia</trialacronym>
    <secondaryid>HREC: 2010.267</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Kidney Failure, Chronic</healthcondition>
    <healthcondition>Anemia</healthcondition>
    <conditioncode>
      <conditioncode1>Blood </conditioncode1>
      <conditioncode2>Anaemia</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Renal and Urogenital</conditioncode1>
      <conditioncode2>Kidney disease</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Renal and Urogenital</conditioncode1>
      <conditioncode2>Other renal and urogenital disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Other interventions - EMAN

Active Comparator: EMAN - Electronic auditing via synchronised blood tests and monthly dosing ESA and Home delivery of ESA from Pharmacy if required

No Intervention: Control - Standard Outpatient Care with usual blood tests and follow up, and varied ESA dosing and frequency times. Patients are responsible for collecting their own ESA from Pharmacy


Other interventions: EMAN
See details on ESA Synchronization and Dosing in Detailed Description Above

</interventions>
    <comparator />
    <control />
    <interventioncode>Other interventions interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Haemoglobin - Haemoglobin (Hb) Targets: % above/within/below target ; % Time Hb above/within/below Target ie. Hb 10 to 12g/dL.</outcome>
      <timepoint>12 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>All Cause Hospitalisation - Same day and Non Same Day Hospitalisation analysis, Total Hospitalisations</outcome>
      <timepoint>12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Outpatient Review Numbers</outcome>
      <timepoint>12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Primary Care review Numbers</outcome>
      <timepoint>12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cardiovascular Hospitalisation</outcome>
      <timepoint>12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cerebrovascular Hospitalisation</outcome>
      <timepoint>12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Peripheral Vascular Hospitalisation</outcome>
      <timepoint>12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Thrombosis Events - Venous and Arterial</outcome>
      <timepoint>12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Renal Replacement Therapy Commencement - Dialysis and Renal transplantation</outcome>
      <timepoint>12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Deaths</outcome>
      <timepoint>12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Quality of Life</outcome>
      <timepoint>12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Missed Doses of ESA</outcome>
      <timepoint>12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Fe Targets</outcome>
      <timepoint>12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Blood Transfusion Numbers</outcome>
      <timepoint>12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Fe Transfusion Numbers</outcome>
      <timepoint>12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Total Adverse Events</outcome>
      <timepoint>12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Anaemia Co-Ordinator Time</outcome>
      <timepoint>12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pharmacy Time</outcome>
      <timepoint>12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Courier Costs</outcome>
      <timepoint>12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Ambulance Transfer Numbers</outcome>
      <timepoint>12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cardiac and Vascular Biomarker Analysis - N Terminal Pro-Brain Natruretic Peptide, Interleukin-6, Tumour Necrosis Factor alpha, High Sensitivity C Reactive Protein</outcome>
      <timepoint>12 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Written informed consent

          -  Age &gt; 18 years

          -  Chronic renal anaemia already on ESA therapy as defined by Pharmaceutical Benefits
             Scheme Criteria</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Pregnancy

          -  Significant acute bleeding such as overt gastrointestinal bleeding

          -  A known haematological cause for anaemia

          -  Known metastatic malignancy

          -  Present participation in another interventional clinical trial  Known
             hypersensitivity to recombinant human erythropoietin, polyethylene glycol or to any
             constituent of the study medication</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate />
    <actualstartdate>1/12/2011</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>102</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/12/2012</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>Western Health - Footscray</hospital>
    <postcode>3011 - Footscray</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Western Health, Australia</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>Aims:

        1. To establish an electronic process for CKD anaemia management using monthly synchronized
           dosing of erythrocyte stimulating agents (ESA).

        2. To compare this electronic process with "present anaemia management" in the traditional
           outpatient setting.

        3. To monitor Hb targets and clinical endpoints of study groups to model a larger
           multicentre study focusing on these endpoints.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01763242</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Craig L Nelson, MBBSFRACPPhD</name>
      <address>Western Health, Australia</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>